Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Kineta Inc KANT

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

PR Newswire December 2, 2019

Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

PR Newswire November 7, 2019

Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

PR Newswire November 6, 2019

Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

PR Newswire October 24, 2019

Proteostasis Therapeutics to Host Cystic Fibrosis Summit on Disparity in Access to CFTR Modulators Based on Geography Featuring Members of the Cystic Fibrosis Community and Thought Leaders

PR Newswire October 21, 2019

Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

PR Newswire September 26, 2019

Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

PR Newswire September 19, 2019

Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

PR Newswire August 7, 2019

Proteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis

PR Newswire July 25, 2019

Proteostasis Therapeutics Announces Management Changes and Appointments

PR Newswire July 23, 2019

Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis

PR Newswire June 4, 2019

Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference

PR Newswire June 3, 2019

Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

PR Newswire May 15, 2019

Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

PR Newswire May 13, 2019

Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

PR Newswire May 8, 2019

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Benzinga.com  March 26, 2019

Mid-Afternoon Market Update: DarioHealth Falls Following Q4 Results; Avaya Shares Jump

Benzinga.com  March 25, 2019

Mid-Morning Market Update: Markets Open Lower; Winnebago Industries Posts Mixed Q4 Results

Benzinga.com  March 25, 2019

Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients

PR Newswire March 25, 2019

Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors

PR Newswire March 7, 2019